Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Global Forecast 2024-2030

Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Global Forecast 2024-2030

The Antiviral Therapeutics Market size was estimated at USD 75.53 billion in 2023 and expected to reach USD 82.01 billion in 2024, at a CAGR 8.28% to reach USD 131.82 billion by 2030.

Antiviral therapeutics are therapeutics specifically designed to target viral pathogens and inhibit their replication, thereby alleviating the symptoms and spread of viral diseases. Antiviral drugs are used in various healthcare settings, ranging from hospitals to specialty clinics and home care. They are prescribed for the treatment of diverse viral infections, including influenza, hepatitis, Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), and the recent SARS-CoV-2. The rising prevalence of various chronic and viral diseases worldwide is expanding the need for antiviral therapeutics. Growing pharmaceutical research and development activities with increasing healthcare expenditure are driving the growth of the antiviral therapeutics market. Side effects associated with antiviral drugs high cost of development of medication hampers the growth of antiviral therapeutics. Growing research and development activities to develop antiviral therapeutics by market vendors are expected to create opportunities for market growth.

Regional Insights

In the Americas, the antiviral therapeutics market is highly developing due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of viral infections. Innovative treatment regimens and a strong focus on research & development (R&D) have been catalyzed by significant investment from both the public and private sectors. European Union (EU) countries collectively represent a significant market, with overarching regulations governed by the European Medicines Agency (EMA). High standards of healthcare and a relatively wealthy population translate to a strong consumer need for the latest therapeutic options. The prevalence of universal health coverage across many EU countries means that purchasing behavior is largely determined by regulatory endorsements and national health care policies. The Middle East and Africa (MEA) presents a diverse market with varying degrees of access to healthcare. Wealthier nations in the Middle East have the financial resources to invest in modern therapeutics, while many African countries face significant barriers to access. Asia-Pacific region is rapidly expanding its presence in the antiviral therapeutics market, marked by increasing investment in pharmaceutical R&D and a large population base requiring medical treatment. The growing availability of local manufacturing and government initiatives in the region to improve healthcare access is driving market growth in Asia-Pacific.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Antiviral Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising Prevalence of Viral Diseases Including HIV and Hepatitis
    • Application of Antiviral Therapeutics in Pediatric Care and Respiratory Diseases
    • Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
    • Market Restraints
      • Relatively High Cost Associated with Antiviral Drug Treatment
      • Market Opportunities
        • Advancements in Molecular Biology Promoting Drug Development
        • Improved Testing and Analysis of Viral Infections
        • Market Challenges
          • Adverse Effects of Antiviral Drugs
          • Market Segmentation Analysis
            • Drug: Growing usage of influenza antiviral drugs are used to treat and prevent influenza.
            • Therapy: Rising inclination towards DNA polymerase inhibitors for the management of HSV and VZV
            • Distribution: Growing adoption of online pharmacy with the rising digital transformation initiatives
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antiviral Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antiviral Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
              
              Gilead Sciences, Inc. and Assembly Biosciences, Inc. announced a comprehensive 12-year strategic partnership. This alliance is set to boost the development of groundbreaking antiviral agents, concentrating on Assembly Bio’s core competencies in combating herpesviruses, hepatitis B (HBV) and hepatitis D virus (HDV).
              
              FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults
              
              The U.S. Food and Drug Administration has officially approved Paxlovid, an oral antiviral regimen consisting of nirmatrelvir and ritonavir tablets specifically designed for at-home administration to treat adult patients with mild-to-moderate COVID-19 who are at an increased risk of developing severe illness, which can lead to hospitalization or even fatality. This authorization marks Paxlovid as the first oral antiviral medication and the fourth therapeutic overall to receive FDA approval for combatting COVID-19 among adults.
              
              Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
              
              Shionogi & Co., Ltd updated their intensive clinical development initiatives for ensitrelvir, a pioneering oral medication designed to combat COVID-19. Known commercially as Xocova within Japan, ensitrelvir has secured emergency use authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for treating SARS-CoV-2 infections, based on favorable outcomes in the Asia-conducted Phase 3 segment of a combined Phase 2/3 clinical trial involving non-hospitalized subjects. As Shionogi continues to pursue global recognition, numerous Phase 3 clinical trials are being conducted to validate the safety profile and efficacy of ensitrelvir across diverse patient demographics.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antiviral Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Antiviral Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Limited, AstraZeneca PLC, Atea Pharmaceuticals, Inc., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Ltd., Cocrystal Pharma, Inc., Daiichi Sankyo Company, Ltd., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Labs Limited, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Syngene International Limited, Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., Venatorx Pharmaceuticals, Inc., Viatris Inc., and Zydus Lifesciences Limited.
            
            Market Segmentation & Coverage
            
            This research report categorizes the Antiviral Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Drug
              • Hepatitis Antiviral Drug
              • Herpes Antiviral Drug
              • HIV Antiviral Drug
              • Influenza Antiviral Drug
              • Therapy
                • DNA Polymerase Inhibitors
                  • Non-nucleosides
                  • Purine Nucleoside Analogues
                  • Pyrimidine Nucleoside Analogues
                  • Neuraminidase Inhibitors
                  • Protease Inhibitors
                  • Reverse Transcriptase Inhibitors
                    • Nonnucleoside RTIs
                    • Nucleoside RTIs
                    • Nucleotide RTIs
                    • Distribution
                      • Hospital Pharmacy
                      • Independent Pharmacy & Drug Store
                      • Online Pharmacy
                      • Region
                        • Americas
                          • Argentina
                          • Brazil
                          • Canada
                          • Mexico
                          • United States
                            • California
                            • Florida
                            • Illinois
                            • New York
                            • Ohio
                            • Pennsylvania
                            • Texas
                            • Asia-Pacific
                              • Australia
                              • China
                              • India
                              • Indonesia
                              • Japan
                              • Malaysia
                              • Philippines
                              • Singapore
                              • South Korea
                              • Taiwan
                              • Thailand
                              • Vietnam
                              • Europe, Middle East & Africa
                                • Denmark
                                • Egypt
                                • Finland
                                • France
                                • Germany
                                • Israel
                                • Italy
                                • Netherlands
                                • Nigeria
                                • Norway
                                • Poland
                                • Qatar
                                • Russia
                                • Saudi Arabia
                                • South Africa
                                • Spain
                                • Sweden
                                • Switzerland
                                • Turkey
                                • United Arab Emirates
                                • United Kingdom
                                
                                
                                Please Note: PDF & Excel + Online Access - 1 Year